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ABSTRACT 
Studies associating prothrombin G2021 OA (FIIG2021 OA), Factor V Lei den 
(FVL), and Factor XIIIV34L (FXIII-A V34L), Factor VII R353Q (FVII R353Q), 5, 10-
Methylenetetrahydrofolate reductase A1298C (MTHFR A1298C), and Interleukin-6 -174 
G/C (Il-6 -17 4 G/C) with myocardial infarction (MI) have yielded conflicting results. 
Complicated gene-gene interactions, small sample sizes and heterogeneous genetic and 
environmental backgrounds may contribute to conflicting results. Simultaneous analysis 
of multiple gene variants in a large sample size from a genetically isolated population 
may overcome these weaknesses. Genotyping was performed in 500 MI patients and 500 
controls from the genetically isolated Newfoundland population to determine the 
prevalence of these gene variants and association with MI. Gene-gene interactions were 
also analyzed. The prevalence of combined carriers of FXIII-A V34L and FIIG20210A 
alleles was 12-fold higher in MI patients compared with controls (P = 0.002) and with 
92% penetrance. There was disequilibrium of FXIII-A V34L allele to MI patients 
carrying FIIG2021 OA as a genetic background. 
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INTRODUCTION 
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1.1 Myocardial Infarction 
Despite increased attention to cardiovascular disease, myocardial infarction (MI) 
remains the leading cause of morbidity and mortality in North America, Europe and much 
of Asia1'2. It is recognized as a multifactorial complex disease resulting from such 
components as lifestyle (activity levels, smoking and diet), atherosclerosis, thrombophilia 
and inflammation, as well as the genes which control these. The level at which an 
individual's genetics contribute to the development of an MI is still the subject of much 
debate, however, the role of genetic inheritance is strongly supported by the predictive 
value of a family history for premature ischemic disease3'4'5. Studies in twins indicate a 
greater genetic risk in monozygotic compared with dizygotic twins for ischemic heart 
disease6, and susceptibility to death from coronary heart disease7, and adoption studies 
have shown that much of the excess risk is genetic rather than environmental6 '7 . The 
relevance of genetic factors in determining the risk of MI is also supported by studying 
the incidence of disease in migrating populations. The Canadian Inuit, for example have 
maintained their low risk of MI in spite of adaptation to Western lifestyle8, suggesting 
that genetic factors are indeed important to disease development. Thus far, when genetic 
risk for MI is identified by gender, it is greater in women than in men7'9. MI aggregates in 
families but is not consistent with Mendelian transmission which is compatible with its 
multifactorial pathogenesis10 . Prevention ofMI has long been focused on identification of 
traditional cardiovascular risk factors (such as smoking, hyperlipidemia, hypertension, 
and obesity) that are related to atherosclerosis. However, approximately 30%-50% ofMis 
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occur m patients without traditional cardiovascular risk factors 11 which has lead to 
extensive study further searching for novel genetic and environmental risk factors. 
Thrombosis is one of the most common pathological findings in MI12 '13 . Antithrombotic 
agents such as aspirin have been shown to be beneficial in primary and secondary 
prevention of arterial thrombosis 14 . Studies have recently attempted to identify genetic 
prothrombotic risk factors which associated with MI. 
1.1.1 Clinical Features of Myocardial Infarction 
A myocardial infarction occurs when myocardial tissue is deprived of oxygen 
resulting in rapid tissue necrosis15 which causes a reduced stroke output from the cardiac 
muscle. This most commonly results from the narrowing and eventual occlusion of 
coronary arteries due to the development and rupture of atherosclerotic plaques and the 
ensuing thrombotic reactions. Chest pain is the most common symptom of an MI: 
typically, it is described as tightness, squeezing, pressure, aching or heaviness. The pain is 
located in the front and center of the chest and can radiate to the left arm, back, neck or 
jaw. Associated symptoms include shortness of breath, nausea, vomiting, and profuse 
sweating. The amount of tissue necrosis is dependant on the size and location of the 
infarction and the rapidity with which blood flow can be re-established by pharmacologic 
or mechanical modalities. After total occlusion myocardial necrosis is complete in 4-6 
hours. Flow to an ischemic area must remain above 40% of pre-occlusion levels for that 
area to survive15 . 
To confirm the diagnosis of an MI, an EKG (electrocardiogram) and blood tests 
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are performed. During an MI, the EKG goes through a series of abnormalities. The initial 
abnormality is called a hyperacute T wave. This is a T wave that is taller and more 
pointed than the normal T wave. The abnormality lasts for a very short time, and then 
elevation of the ST segment occurs. This is the hallmark abnormality of an acute MI15 . It 
occurs when the heart muscle is being injured by a lack of blood flow and oxygen. This is 
followed by T wave inversions. Over time, when the heart muscle cells actually die, these 
abnormalities are replaced with Q waves. When a Q wave develops after an MI, it is 
called a Q-wave MI and usually corresponds to a transmural MI (entire thickness of the 
heart muscle wall has died). When a Q wave does not develop after an MI, it is called a 
non-Q-wave MI and usually corresponds to non transmural heart muscle death or a 
subendocardial MI (heart muscle just under the inner lining of the heart has died). An 
EKG can not only tell a physician if an MI is present but can also show the approximate 
location of the heart attack and often which artery is involved. 
The majority of MI patients can be identified after the event by analysis of blood 
chemistry for the cardiac proteins. As heart muscle cells die, cellular proteins are released 
into the blood where they are not normally and found, or are normally present in 
extremely small quantities, and can be detected quite easily. This does not occur instantly 
and usually levels take several hours following an MI to reach their peak. These proteins 
include CPK (creatine phosphokinase), Myoglobin, and Cardiac Troponin 115 . Some of 
these markers occur in other cells and can limit their usefulness in diagnosing an MI, and 
thus the majority of MI patients are in fact identified after the event by analysis of blood 
chemistry for Cardiac Troponin I. This is a contractile protein that is normally found in 
only trace amounts in serum and is released in greater quantities only when myonecrosis 
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occurs. Cardiac Troponin I levels become abnormally high in serum 3-6 hours after an 
MI, and remain elevated for up to14 days 15 . 
1.2 Mechanisms of Disease in Myocardial Infarction 
As described previously, MI occurs when myocardial tissue is deprived of oxygen 
resulting in rapid tissue necrosis. This oxygen deprivation results when a blockage occurs 
in arteries leading to the myocardial muscle, preventing oxygen-rich blood from reaching 
the heart. This blockage is generally the result of atherosclerosis, or a combination of 
atherosclerosis and thrombosis. 
1.2.1 Development of Atherosclerotic Plaques 
An atherosclerotic lesion occurs when endothelial cells, activated by risk factors 
such as hyperlipoproteinemia, express adhesion and chemoattractant molecules that 
recruit inflammatory leukocytes such as monocytes and T-lyrnphocytes. The endothelium 
has a critical role in vascular haemostasis. It modulates regulation of the permeability of 
plasma lipoproteins, adhesion of leukocytes, release of prothrombotic and anti thrombotic 
factors, growth factors and vasoactive substances16 . Impairment of these functions is 
believed to play a central role in development of atherosclerosis17 . Extracellular lipid and 
low-density lipoprotein (LDL) will begin to accumulate in the intima of the arterial wall 
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at this stage. If these responses continue unabated, they can thicken the artery wall (which 
compensates by gradual dilation) so that up to a point the lumen remains unaltered, a 
phenomenon known as "remodelling"18 . LDL particles trapped in the artery can undergo 
progressive oxidation19 . Monocytes recruited to the artery wall become macrophages and 
express scavenger receptors that bind lipids and oxidized LDL, and then internalize them. 
This internalization leads to the formation of lipid peroxides and facilitates the 
accumulation of cholesterol esters and the macrophages then become lipid-laden foam 
cells20 . Leukocytes and resident vascular wall cells can secrete inflammatory cytokines 
and growth factors that amplify the leukocyte recruitment and cause smooth muscle cell 
migration and proliferation. As the lesion progresses inflammatory mediators cause 
expression of tissue factor (a potent procoagulent) and of matrix degrading proteinases 
that weaken the fibrous cap of the plaque. 
1.2.2 Thrombosis 
Evidence now supports the concept that the protective fibrous cap is not actually 
fixed or static, but instead actually undergoes continuous and dynamic remodelling and 
displays considerable metabolic activitl 1. If the fibrous cap ruptures at a point of 
weakening, coagulation factors in the blood can gain access to the thrombogenic, tissue 
factor containing lipid core, causing thrombosis on non-occlusive atherosclerotic plaques. 
If the balance between prothrombotic and fibrinolytic mechanisms prevailing at that 
particular region and at that particular time is unfavourable, occlusive thrombus causing 
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acute coronary syndromes may result. When the thrombus resorbs, products associated 
with thrombosis such as thrombin and mediators released from degranulating platelets 
(including platelet-derived growth factor and transforming growth factor-~) can cause a 
healing response, leading to increased collagen accumulation and smooth muscle cell 
growth. In this manner, the fibrofatty lesion can evolve into an advanced fibrous and 
often calcified plaque that may cause significant stenosis, and produce symptoms of 
stable angina pectoris. In some cases occlusive thrombi arise not from fracture of the 
fibrous cap but from superficial erosion of the endothelial layer. The resulting mural 
thrombus, again dependant on local prothrombotic and fibrinolytic balance, can cause 
acute myocardial infarction. 
1.2.2.1 The Coagulation and Anti-Coagulation Systems 
The haemostatic process is a carefully controlled balance of prothrombotic and 
anti-thrombotic factors within the vasculature. The prothrombotic mechanisms of 
coagulation activation and platelet adhesion/aggregation are balanced by naturally 
occurring anticoagulants, endothelial cells, and the fibrinolytic system. In the event of a 
blood vessel injury, the thrombotic process begins with injured endothelium or denuded 
vascular surfaces. When the subendothelium is disrupted, both the intrinsic and extrinsic 
blood coagulation pathways commence their actions. In the intrinsic pathway, von 
Willebrand factor (vWf) molecules are rapidly localized to the exposed collagen, 
tethering platelets to the wound22 . Platelet glycoproteins then activate the platelets 
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causing them to adhere to one another23 '24 . Lipopolysaccharides from platelets and cell 
surfaces then activate Factor XII which in turn activates Factor XI, which plays a role in 
the activation of Factor IX ofthe extrinsic pathway. 
During this phase of platelet activation the extrinsic pathway of blood coagulation 
is activated. Initiation of the coagulation cascade is largely due to exposure of the various 
blood elements to non-vascular cell tissue factor. Tissue factor binds to activated factor 
VII, or FVIIa and the resulting enzyme complex activates (in the presence of Ca2+) factors 
IX and X (converting both to FIXa and FXa) of the intrinsic and common coagulation 
pathways, respectively. FIXa in turn activates additional factor X. Once activated, FXa 
converts prothrombin to the serine protease thrombin (factor IIa) in a reaction that is 
accelerated by factor Va. Factor XIII is the last enzyme to be activated in the blood 
coagulation cascade. It is converted to FXIIIa, through a catalytic reaction with FIIa. In 
the final step of the coagulation pathway, thrombin cleaves fibrinogen to form fibrin 
monomers which then polymerize by factor XIIIA catalyzing the crosslinking between 
fibrin molecules to form a chemically stable clot rendering it less susceptible to 
proteolytic cleavage25 . Thrombin then also further activates cofactors VIII and V thereby 
further serving to self-propagate the coagulation mechanism. Simultaneously platelets 
adhere to exposed extracellular matrix proteins, undergo activation by thrombin and other 
agonists, and aggregate to form a platelet-fibrin thrombus. 
This prothrombotic process is regulated and balanced by the fibrinolytic system, 
consisting of natural anti-coagulants such as antithrombin, activated protein C (APC) and 
its cofactor (protein S), as well as tissue factor inhibitor. The fibrinolytic system is 
concomitantly activated by plasminogen activators released from endothelial cells, 
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leading to the production of the active plasmin and eventual degradation of the fibrin 
clot26 . In the presence of endogenous heparin sulfate, the rate of inactivation is increased 
by a factor of several thousand. In the presence of thrombomodulin bound to endothelial 
cells, Fila activates protein C, which in tum cleaves and inactivates FVIIIa and FV a. 
Endothelial cells normally have an antithrombotic effect, largely due to membrane-bound 
thrombomodulin, which is responsible for activating protein C27 . Other antithrombotic 
endothelial functions include platelet inhibition due to release of prostacyclin and nitrous 
oxide. An outline of the blood coagulation system is shown in figure-1. 
9 
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1.2.2.2 Thrombotic Imbalance 
Congenital and acquired hypercoagulable states arise when there is an imbalance 
between the anticoagulant and prothrombotic activities of plasma in which the 
prothrombotic activities dominate28-30 . There are many recognized acquired 
prothrombotic risk factors such as age, obesity, oral contraceptives, surgery, trauma, 
paralysis. All of these factors can cause a tendency towards thrombosis resulting from 
such events as a decrease in blood flow, injury to the vessel wall, and a change in the 
systemic balance of the procoagulant and anticoagulant factors. Endothelial cells 
normally have an antithrombotic effect, largely due to membrane-bound 
thrombomodulin, which as previously stated, is responsible for activating protein C27 . 
According to this scheme, one might predict that the loss of a circulating anticoagulant 
would cause a shift in the haemostatic balance and thereby promote a diffuse thrombotic 
diathesis: in fact, this prediction does not hold true31 . Systemic alterations in the 
haemostatic mechanism typically g1ve nse to local thrombotic lesions in discrete 
segments of the vascular tree. The pathophysiologic basis for this observation is poorly 
understood: the conventional wisdom is that the focal lesions are attributable to 
superimposed defects in the vascular wall or blood flow. In other words, the phenotypic 
fate of systemic hypercoagulable states rests on the ability of these two mechanisms to 
compensate for a uniform change in the haemostatic balance. As mechanistic studies have 
progressed, the pathophysiologic mechanism for thrombosis with many of the acquired 
risk factors has been associated with perturbations in procoagulant factors, the 
vasculature, or blood flow. 
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1.3 Candidate Genetic Thrombotic Risk Factors in Myocardial Infarction 
Recognition of familial tendencies for thrombosis initially led to a search for 
genetic abnormalities in the coagulation system, and the central role of thrombosis in 
acute coronary ischemia has gained attention. The first mutations associated with 
thrombophilia were loss-of-function mutations in antithrombin32 , protein C33 , and protein 
S34. Heterozygous individuals have an increased risk for venous thromboembolism. These 
disorders are rare and show high allelic heterogeneity, thus making genetic testing 
difficult. For example, more than 70 different mutations in protein C have been 
described35 . Of patients with thrombophilia, genetic deficiencies of the natural 
anticoagulants have been found in less than 20% of the cases. Deficiency of the 
profibrinolytic factor, plasminogen, has been associated with thrombophilia, but this 
association is less clear than that of the natural anticoagulants36 . 
Endothelial causes for a thrombotic tendency could be genetic dysregulation of 
the antithrombotic mechanisms or endothelial denudation with exposure ofprothrombotic 
plaque and extracellular proteins as occurs with atherosclerosis. Additionally, changes in 
blood flow may cause thrombosis due to stasis but may also effect endothelial gene 
0 37 
expressiOn . 
The search to explain thrombophilia in familial patients for whom no cause could 
be found led to sequencing of the genes of many of the procoagulent proteins. This 
process in tum led to the description of relatively common single nucleotide 
polymorphisms (SNPs) in many of these genes, however, the functional implications of 
most of these SNPs were not always clear. Certain polymorphisms associated with 
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thrombosis have been found in many of the genes coding for proteins in the coagulation 
pathway including prothrombin or factor II, factor V, factor VII and factor XIII and 
others. 
1.3.1 Factor V Leiden 
The gene which codes for blood coagulation factor V is located on chromosome 
1 q21 - 1 q25, has 25 exons and produces a 300-kd multi domain glycoprotein. Activated 
factor V (FVa) is a cofactor protein in the prothrombinase complex that, together with the 
serine protease factor Xa, is responsible for the conversion of prothrombin or FII to the 
active enzyme thrombin, or Fila. Activated protein C (APC) down-regulates the 
functionality of this complex by proteolytic degradation of factor Va at two primary 
cleavage inactivation sites, amino acids Arg506, and Arg306. Patients resistant to the 
activity of APC were described by Dahlback et. al in1993 38 , and the molecular basis for 
this defect was shown by Bertina et. al to be a point mutation in the factor V gene - a 
G>A transition at nucleotide 1691 (G1691A), which they labelled factor V Leiden 
(FVL)39 . The FVL mutation results in an arginine-glutamine substitution at amino acid 
506 (Arg506Gln), the site of the first molecular cleavage of factor Va by APC. This 
substitution results in a diminished ability of APC to cleave factor V a and therefore 
causes continued formation of thrombin by the prothrombinase complex (i.e., APC 
resistance). Factor V Lei den is commonly accepted as the most common genetic factor 
associated with APC resistance; 95% of individuals with functional APC resistance carry 
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the FVL polymorphism40• The FVL polymorphism is common in the Caucasian 
population with a frequency ranging anywhere from 2% -15%41 -43 , but averaging 5%. 
FVL frequency can vary a great deal among other ethnic populations, being extremely 
rare in African and Asian populations41 ,42'44 to higher and very high in some populations 
of middle-eastern and Arabic descent45 -47 . The high prevalence of FVL did raise the 
question of whether the point mutation was the result of a founder effect or whether it is a 
frequent, recurring mutation in the factor V gene. An extensive haplotype analysis using 
six polymorphic sites in the factor V gene supported a single origin for FVL, and it was 
estimated that it occurred approximately 21000 years ago 48 . 
The FVL mutation is detected in up to 40% of patients with venous thrombosis39, 
imparting an eightfold increased risk for heterozygotes and 80-fold increase in 
homozygotes49 . FVL has been shown in clinical studies to be the most common risk 
factor for deep venous thrombosis (along with the prothrombin G2021 OA 
polymorphism)50 and is also suggested to act a risk factor for pulmonary embolism, 
cerebral vein thrombosis, and superficial thrombophlebitis51 . FVL has also been studied 
for an association with arterial thrombosis (such as MI), however the relationship is not 
yet clear. An association between FVL and arterial thrombotic disease was first suggested 
by Holm et. al who reported two young women with MI and homozygosity for the FVL 
mutation 52. Subsequent association studies on arterial thrombosis, however, have 
provided mixed results. Several studies have shown no association between FVL and 
coronary artery disease or MI53 -61 , even among patients who developed acute coronary 
syndromes at a young age62 '63 . In contrast, Rosendaal et. al reported an almost 2.5 times 
greater risk of non-fatal MI among female carriers of FVL versus the normal population, 
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and a great deal higher risk among smokers in the patient group (32-fold increased risk 
compared to non-smoking women without the FVL mutation)64 . 
The association between FVL and Myocardial Infarction has been examined in at 
least three large case-control studies. Doggen et. al examined 560 middle-aged-to-elderly-
Dutch-men and reported an increased risk of MI associated with heterozygosity for FVL 
that was most pronounced in men with other cardiovascular risk factors65 . Masourati et al 
compared 3 groups of subjects: one group consisted of 107 patients with early onset 
myocardial infarction but no significant coronary artery stenosis; another group of 244 
patients with myocardial infarction and significant coronary artery stenosis; a third group 
of 400 healthy controls. Factor V Leiden was found in 12.1% patients (13 of 107) who 
had a myocardial infarction without significant coronary artery stenosis, in 4.5% of the 
patients who had a myocardial infarction with significant coronary artery stenosis ( 11 of 
244, p = 0.01) and in 5% of the controls (20 of 400, p = 0.01), giving respective odds 
ratios of2.93 (CI95: 1.18-7.31) and 2.63 (CI95: 1.19-5.78) for MI associated with factor 
V Leiden when MI patients without significant coronary artery stenosis were compared to 
controls or to patients with significant coronary artery stenosis, respectively. 66 . Most 
recently, the Copenhagen City Heart Study reported an investigation of 20- to 95-year-old 
participants without cardiovascular disease (control population, n = 7907) or participants 
diagnosed with MI (n = 469), ischemic stroke (IS) (n = 231), or non-MI-ischemic heart 
disease (non-MI-IHD) (n = 365). In addition, 3 independent patient populations with MI 
(n = 493), IS (n = 231), or non-MI-IHD (n = 448) were included. They characterized FVL 
genotype; major cardiovascular risk factors; and MI, IS, and non-MI-IHD incidence and 
prevalence. Odds ratios and relative risks of MI in FVL carriers (heterozygotes + 
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homozygotes) versus noncarriers were found to be 1.24 and 0.83 in case-control and 
prospective studies, respectively. Corresponding odds ratio for IS were 0.92 (95% CI, 
0.56-1.53) and 0.68 (0.45-1.04), and for non-MI-IHD 1.01 (95% CI, 0.71-1.44) and 0.97 
(0.66-1.42) suggesting that FVL is not associated with MI, IS, or non-MI-IHD67 . 
Obviously, with the large amount of conflicting data that has been presented, the 
relationship between the factor V Leiden mutation and myocardial infarction has not yet 
been fully elucidated. 
1.3.2 Prothrombin 20210 G>A 
The gene coding for factor II, or prothrombin is located on chromosome 11 p 11-
q 12. The gene is 21 kb long and contains 14 exons separated by 13 intervening 
sequences. The exons range in size from 25 to 315 basepairs, while the introns range from 
84 to 9,447 basepairs. Intervening sequences constitute 90% of the gene68 , and after 
translation the gene product has a mass of 83kDa prior to cleavage69 . As stated 
previously, thrombin, (the end product of the cleaving of prothrombin) plays a central 
role in haemostasis in that it converts fibrinogen to fibrin, but it also activates factors V, 
VIII, XIII, and protein C. Thrombin is also a potent activator of platelets. Knowing the 
central role of thrombin in the coagulation cascade, Poort et. al investigated the 
prothrombin gene as a as a candidate gene for venous thrombosis in patients from 
families with unexplained thrombophilia70 . They identified a G>A transition at nucleotide 
20210 in the 3' untranslated region of the prothrombin gene (prothrombin G2021 OA or 
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FII 020210A). The FII 20210A allele was present in 18% of unselected patients with a 
first, objectively confirmed episode of deep-vein thrombosis and a family history of the 
disease (n=28) compared with 2% of health controls (n=1 00) which gives a odds ratio of 
2.8 (95% CI: 1.4 - 5.6), suggesting the presence of the FII 02021 OA mutation may 
increased the risk of deep-venous thrombosis. The FII 2021 OA allele has been found to be 
present at a frequency of 2% most Caucasian populations71 .Current estimates are that up 
to 25% of patients presenting with deep venous thrombosis carry either the FVL 
mutation, the prothrombin 02021 OA variant, or both 5°. Double heterozygotes for FVL 
and prothrombin 020210A are at greatly increased risk for deep venous thrombosis63 : 
Emmerich et. a! (2001)50 reviewed and pooled the analysis of 8 case-control studies, 
comprising a total of 2310 venous thrombosis cases and 3204 healthy controls, in order to 
precisely estimate the risk of deep venous thrombosis in patients bearing both mutations 
(double heterozygotes). Odds ratios were 4.9 (95% CI; 4.1-5.9) for FVL carriers, 3.8 
(95% CI; 3.0-4.9) for the prothrombin 020210A carriers, and 20.0 (95% CI; 11.1-36.1) 
for double heterozygotes. Twelve percent of patients heterozygous for factor V Leiden 
were also heterozygous for factor II 02021 OA and conversely 23% of patients 
heterozygous for the FII 2021 OA allele were also heterozygous for factor V Lei den 5°. 
The prothrombin 02021 OA mutation has been shown to be associated with a 50% 
increase in circulating prothrombin in carriers from several different ethnic populations36' 
70
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. However, the mechanism by which this base pair substitution increases the plasma 
levels of prothrombin is not yet clear. Poort et. a! hypothesized in their original paper that 
the 2021 OA allele may cause a higher translation efficiency or higher stability of the 
transcribed RNA. The 0/ A sequence variation is located at the last position of the 3' 
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untranslated region70 at or near the cleavage site in the mRNA precursor to which the 
poly-A tail is added. Three conserved sequences in mRNA precursors located in the 
vicinity of this site, are required for cleavage and polyadenylation: The AAUAAA 
sequence, the nucleotide to which the poly-A tail is added, and the region downstream of 
this nucleotide74'75 . Generally, the nucleotide to which the poly-A tail is added is an A74-
76, mostly preceded by a C74 •77 . As a consequence of the G to A transition at position 
20210, a CA dinucleotide instead of GA has been introduced at or near the cleavage and 
polyadenylation site. However, in vitro experiments so far do not support a hypothesis in 
which this nucleotide substitution results in an increased efficiency of the 3' end 
formation. 
As with factor V Leiden, the relationship between the FII G2021 OA mutation and 
risk for arterial thrombosis such as myocardial infarction is not completely clear. Several 
published studies have found no association between the 2021 OA allele and the risk of MI 
or coronary artery disease78-87 , while others have identified a correlation between the 
two88-92 . However, the statistical power of many of these studies to determine an 
association is limited due to the low frequency of the FII 2021 OA allele within the general 
population. Interestingly, in a pooled analysis of 1115 patients and 1888 controls from 
five studies, the FII 20120A allele was significantly associated to patients with MI (OR= 
2.5; 95% CI 1.5- 4.3)72 . In a large case-control study of 560 patients with MI (under age 
70 years) and 646 healthy control subjects, the 2021 OA allele was associated with a 
mildly increased risk ofMI (OR= 1.5; 95% CI 0.6 -3.8) that substantially increased to 3-
6 fold in the presence of traditional cardiovascular risk factors such as smoking and 
hypertension91 . In contrast to this conclusion, Boekholdt et. a/93 (2001) reviewed data 
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from thirteen prevwus studies72 '81 '82 '84-92 . The patients were re-examined usmg more 
stringent MI diagnostic criteria in order to better evaluate the conclusions reached. Nine 
of these studies were excluded because of low stringency in the diagnostic criteria for 
MI86•87 , or because of inadequate delineation of cases 72 , or an inadequate spectrum of 
cases (meaning small sample size, or patients under age 55)79·84•85 ·88 ·90·92 . A pooled 
analysis of the four remaining studies81 '83 •86 '91 included a total of 1434 patients and 2943 
controls, and showed no association between the FI 20210A allele and MI (OR 0.89, 95% 
CI 0.59-1.35, p=0.6). Obviously, as with factor V Leiden, the role of the prothrombin 
G2021 OA mutation in the pathogenesis of myocardial infarction is not yet fully 
understood. 
1.3.3 Factor XIII V34L 
Factor XIII is a protein with transglutaminase activity consisting of two A 
subunits arranged as a dimer in association with two B subunits in a heterotetrameric 
structure (A2B2) of 320 kd94'95 . The gene encoding the A subunit of human factor XIII is 
located on chromosome 6 and contains 15 exons and 14 introns spanning over 160 kb. 
Five distinct functional domains are encoded by separate exons96 . The A subunits of 
FXIII are responsible for transglutaminase activity, and are activated following the 
cleavage of anN-terminal peptide by thrombin97 . The B subunit is a glycoprotein and has 
no known enzymatic activity. It is thought that the B subunit forms a complex with the A 
subunit dimer and protects it from elimination98-101 . Factor XIII is activated by the action 
19 
ofthrombin cleaving an activation peptide of37 amino acid residues from theN-terminal 
end to form the last enzyme generated in the blood coagulation cascade. It is the zymogen 
for fibrinoligase, a transglutaminase, which through an acyl-transfer reaction cross-links 
peptide bound glutamine and lysine residues through isopeptide bonds102 . The main 
physiological task of FXIII is to form intramolecular y-glutamyl-c;-lysine crosslinking 
between fibrin molecules, and also to cross-link a2-plasmin inhibitor to fibrin. 
Crosslinking of fibrin stabilizes the blood clot and protects the newly formed fibrin from 
rapid elimination by the powerful fibrinolytic mechanism103 . 
Previous studies of factor XIII have shown that the A subunit is genetically 
heterogenous and a number of polymorphisms have been identified in the protein 
sequence94•96•103 •104 . Several studies have shown that there is a large range of the A subunit 
transglutaminase activity in the normal population, and it is possible that the different 
levels of activity are related to the inheritance of different allelic variants 105"109 . A 
common G>T transversion in ex on 2 of the A subunit results in the substitution of leucine 
for valine at amino acid residue 34110 . This amino acid substitution is located three 
residues away from the thrombin cleavage activation site104'lll. The 34L variant of factor 
XIII-A has been shown to have a great deal higher enzyme activity and earlier enzyme 
activation than the normal 34V enzyme in both recombinant DNA studies and in plasma 
from normal blood donors 112 ' 113 . Recent studies have pointed towards a decreased risk of 
both venous thrombosis114'115 and myocardial infarction116"118 for carriers of the 34L 
allele. The most widely quoted of these studies compared the frequency of the factor XIII-
A 34L polymorphism in 126 male MI patients and 344 male healthy controls from 
Finland117 . The 34L allele was found to be present at a carrier frequency of 25% in 
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controls and 17% in MI patients (p=0.02, OR 0.59; 95% CI 0.38- 0.93). 
The mechanism of this suggested protection is not immediately obvious as the 
higher activity level of the 34-leucine variant should lead to an increase in resistance of 
fibrin clots to plasmin degradation. While several studies to date have reproduced data 
regarding this protective effect, only one has given data which fits the current 
understanding of the physiological coagulation system and associates the 34L allele of 
factor XIII with an increased risk oflater onset of peripheral artery disease119, however no 
association to an increased risk for MI has yet been reported. 
1.3.4 Factor VII R353Q 
Activated factor VII (FVII) is a vitamin K-dependant serine protease synthesized 
by the liver and secreted as a single chain 48 kDa glycoprotein that plays a central role in 
the extrinsic pathway of blood coagulation. The gene is located on chromosome 13q34, 
consists of 9 exons spanning approximately 12kb, and encodes a mature protein of 406 
amino acids120. Upon endothelial injury, FVII is activated through cleavage by tissue 
factor (factor III) at residue 152 to form FVIIa, which then forms a complex with tissue 
factor, to initiate coagulation by activating both factor IX and factor X, and also 
autocatalytically further activates factor VII 121 ·122 . 
Circulating levels of factor VII vary greatly within the general population and are 
influenced by factors such as oral contraceptives and a high fat diet. FVII coagulant 
activity is associated with high triglyceride and cholesterol levels and has been shown to 
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increase with an increase in body fat 123 . Interest in the relationship between factor VII and 
cardiovascular disease was stimulated by the finding from the Northwick Park Heart 
Study that elevated levels of circulating FVII were related to fatal, but not to non-fatal 
MI. In this prospective study of white males (n=l511) aged 40 to 64 years, circulating 
FVII was found to be strongly associated with coronary risk (62% increased risk, p<O.Ol) 
with a 1 SD increase in FVII levels over the first 5 years of the study124 . Further 
prospective studies, however, have not obtained similar results. Both the PROCAM 
(Prospective Cardiovascular Munster study) 125 and Edinburgh Artery Studies126 failed to 
confirm FVII as an independent risk factor for coronary events. The ECTIM (Etude Cas-
Temoins de l'Infarctus du Myocarde) study found that the control subjects had uniformly 
higher levels of FVII, which tended to mitigate against it having a major role as a 
cardiovascular risk marker127 . It has been shown that genetic factors strongly influence 
factor VII circulating plasma levels and regulate the response to environmental stimuli 128 . 
An adenine to cytosine substitution polymorphism within the FVII gene identified 
by the restriction enzyme Mspl, resulted in a glutamine residue replacing an arginine 
residue at position 353 129. The Arg353Gln (R353Q) site was noted initially to associate 
with a 20% to 30% variance below the group mean in factor VII levels in males and 
females and in different ethnic groups 130. Many subsequent studies have confirmed that 
carriers of the allele coding for Gln353 have lower FVII levels 131 -133and Hunault et al 
have shown that FVII 353Q is secreted with a lower efficiency in vitro 134 . 
The association of the R353Q polymorphism with myocardial infarction is still 
highly controversial. While FVII 353Q was found to associate strongly to circulating 
factor VII levels in MI patients and controls from the ECTIM study, there was no 
22 
difference in genotype frequencies between the two groups. The largest published case-
control study, SMILE (Survival of Myocardial Infarction Long-Term Evaluation) in the 
Netherlands found an association between the FVII 353Q polymorphism and circulating 
factor VII, however, it also found that FVII 353Q was associated with a decreased, rather 
than an increased risk for MI 560 patients vs 644 healthy controls OR 0.80, 95%CI 0.60-
1.06) which was more pronounced in patients younger than 50 years (OR 0.49, CI:, 0.28-
0.84) 135• Most recently, Girelli et al. found that individuals carrying the FVII353Q 
polymorphism had a markedly decreased incidence of myocardial infarction despite 
severe, angiographically documented coronary atherosclerosis. The QQ genotype was 
associated with a 72% reduction of activated factor VII activity compared with the wild 
type genotype. Heterozygote carriers of the Q allele had a 0.4 7 risk of MI compared with 
patients with the wild type genotype ( 411 MI patients vs. 133 healthy controls: 95% CI: 
0.27 to 0.81) 136. Further investigation of the FVIII R353Q polymorphism will be required 
before conclusions can be effectively drawn as to its relationship to MI. 
1.4 Non-coagulation Genetic Risk Factors in Myocardial Infarction 
As MI is a multifactorial and polygenic disease involving several complex and as 
yet unknown interactions between genes and environment, a portion of this study was 
devoted to an investigation of genetic risk factors in MI beyond the blood coagulation 
system, encompassing genes in the inflammation and metabolic pathways. 
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1.4.1 Inflammation 
A consensus has recently emerged that inflammation plays a decisive role in the 
pathophysiology of acute thrombotic events 137 . The inflammatory process which 
ultimately leads to an atherosclerotic plaque is triggered initially by endothelial 
dysfunction 138-140. As described previously, an atherosclerotic lesion occurs when 
endothelial cells, activated by risk factors such as hyperlipoproteinemia, express adhesion 
and chemoattractant molecules that recruit inflammatory leukocytes such as monocytes 
and T -lymphocytes. Leukocytes and resident vascular wall cells can secrete inflammatory 
cytokines and growth factors that amplify the leukocyte recruitment and cause smooth 
muscle cell migration and proliferation. As the lesion progresses inflammatory mediators 
cause expression of tissue factor and of matrix degrading proteinases that weaken the 
fibrous cap of the plaque. Macrophage secretion of interferon gamma can inhibit de novo 
synthesis of interstitial collagen by smooth muscle cells, the major source of the 
extracellular matrix collagen 141 . In addition, inflammatory cytokines and fas ligand, 
which are overexpressed in atherosclerotic plaques, can trigger apoptosis and death of 
these surrounding smooth muscle cells, a critical source of extracellular matrix 
macromolecules in the artery wall 142 . Absence of smooth muscle cells jeopardizes the 
integrity of the fibrous cap because these cells repair and maintain the collagenous matrix 
of the fibrous cap: plaques that rupture have thin and friable fibrous caps because of the 
lack of collagen 143 . Sites of fatal thrombosis where plaques have ruptured typically have 
very few smooth muscle cells144'145 . In addition to local effects of inflammation at the 
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level of the atherosclerotic lesion itself, systemic aspects of the inflammatory response 
may alter thrombotic risk. Inflammation upsets the prevailing homeostatic balance. 
Fibrinogen and plasminogen activator inhibitor circulate at higher concentrations in 
inflammatory states. A given plaque disruption could therefore have a greater chance to 
produce an occlusive thrombus under such conditions 137 . 
1.4.1.1 C-Reactive Protein 
C-Reactive Protein (CRP) is a protein produced by the liver that is present in 
blood serum in relatively large amounts during acute inflammation. Levels of CRP in 
blood serum are otherwise very low (approximately 0.11 mg/dL). CRP is an acute phase 
protein which promotes inflammation, and activates the complement system to stimulate 
chemotaxis of phagocytes146 . As a marker of inflammation, CRP is unique among the 
major plasma proteins in the level of increase that is observed, and that its levels appear 
to be unaffected by hormones and anti-inflammatory drugs, but instead are regulated by 
the proinflammatory cytokines, especially IL-l and IL-6147 . Prospective data from the 
Physicians Health Study indicates that among a population of apparently healthy men, 
baseline levels of CRP are predictive of a first myocardial infarction. Specifically, among 
men free of prior cardiovascular disease those with CRP levels in the highest quartile, a 
threefold increase in risk of developing future myocardial infarctions was observed when 
compared those individuals with CRP levels in the lowest quartile148 . In addition to the 
findings of the Physicians Health Study, CRP levels have been identified as an 
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independent, prospective risk factor in the higher-risk middle-aged men of the MRFIT 
study149, the healthy middle aged men of the MONICA-Ausburg cohort150 and the healthy 
elderly men and women of the CHS and the Rural Health Promotion Project151 . CRP 
levels are known to be related to smoking152 and the MRFIT data indicated that although 
there was no confounding effect, there was an interaction of smoking with CRP: CRP 
better predicted events in smokers than in non-smokers, independently of smoking 
cessation 149 . Consistent with this finding, CRP levels were associated with lifetime 
exposure to cigarette smoke. Taken together these findings raise speculation that CRP, at 
least in some people may mark permanent underlying endothelial damage due in part to 
smoking. It is important to note however, that in the Physicians Health Study CRP 
predicted future events just as well in non-smokers as in smokers, raising the question as 
to whether or not CRP levels were indicative of a response to endothelial damage or are 
in fact an independent risk factor148 . 
1.4.1.2 Interleukin-6 
At the time this research was conducted, no data had been published on functional 
SNPs of the CRP gene, and therefore although CRP levels may be elevated in individuals 
without overt infections or trauma, there is currently no genetic explanation for 
persistently elevated CRP levels in some individuals. Interleukin-6 (IL-6) is a pro-
inflammatory cytokine and a central mediator of the acute-phase response, which together 
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with IL-l stimulates the liver to produce acute phase proteins 153 ; indeed, Il-6 is a primary 
determinant of hepatic production of CRP 154 . The ability ofiL-6 to promote transcription 
ofCRP is mediated, in large part, by its ability to activate the transcription factor STAT3; 
via a tyrosine phosphorylation mediated by the IL-6 receptor complex)155-157 . STAT3 
binds directly to the promoter region of the CRP gene and induces transcription158 •159 . 
Fishman et al. (1998) investigated the 5' regulatory region of the IL-6 gene for 
polymorphisms which may influence expression, and identified a G/C polymorphism at 
position -174. This polymorphism showed a prevalence of 40.3% (95% CI 0.37-0.44) in a 
healthy population (383 men and women from north London, UK.) Individuals carrying 
the -174 C/C genotype showed 0.624-fold lower expression of IL-6 than individuals 
carrying the -17 4G/G genotype. This lower expression was also directly related to 
circulating IL-6 concentrations, as individuals homozygous for the GG genotype had 
approximately twice the plasma level of IL-6 than individuals homozygous for the CC 
genotype (P=0.02/ 60 . This finding was confirmed in several subsequent studies161 -163 . 
Despite this lower level of Il-6 transcription and circulating Il-6 observed in the presence 
of this polymorphism, individuals carrying either of the GC or CC genotypes have been 
found consistently to have significantly higher base-line levels of CRP 164•165 , although the 
mechanism by which this polymorphism increases base-line plasma CRP concentration is 
unknown. Some studies have shown that the IL-6 -174 G/C polymorphism has been 
associated with coronary heart disease and high systolic blood pressure166, and other 
related conditions such as asymptomatic carotid artery atherosclerosis 167 , cardiovascular 
mortality following small aneurisms 168, and peripheral artery occlusive disease169 . The 
mechanism by which this polymorphism influences these conditions is unknown, but 
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believed to be due to its role in inflammation via the regulation of CRP 164-166. Although 
expression of the CRP gene during the acute-phase response is regulated by IL-6, the 
relationship of IL-6 expression levels to baseline plasma CRP levels is mostly unknown. 
To date, only one previous study has attempted to relate the IL-6 -174 G/C polymorphism 
to myocardial infarction, and found no association170 . Despite this result, there remains 
much evidence that IL-6 is related to other cardiovascular disease conditions, and thus 
remains an interesting investigative target as to its relationship with the onset of MI. 
1.4.2 Hyperhomocysteinemia 
Homocysteine is a sulfur-containing amino acid, an intermediate product formed 
during metathionine metabolism and is rapidly oxidized in plasma to the disulfides 
homocystine and cysteine-homocysteine. Plasma/serum total homocysteine, also termed 
homocyst( e )ine, is the sum of homocysteine in all 3 components 171 . Several studies 
published in the early 1990's showed that 12 - 14% of patients with coronary artery 
disease also had familial hyperhomocysteinemia172'173 , and also showed an association 
between high plasma homocysteine concentrations and low concentrations of folate and 
vitamin B6 (because of their role in homocysteine metabolism), as well as an increased 
risk of extracranial carotid artery stenosis in the elderly174 . More than 20 cross-sectional 
and 3 prospective175-180 studies in young and middle-aged patients have shown that high 
levels of homocysteine are associated with an increased risk of MI and stroke. The 
pathogenesis through which homocysteine actually causes vascular damage still remains 
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unclear181 . 
Two major hypotheses have been proposed to explain how homocysteine induces 
its harmful effects: It can damage endothelial cells lining the vasculature, causing blood 
clotting and thus promoting atherosclerotic plaque formation182·183 . Simultaneously, it 
interferes with the vasodilatory effect of endothelial derived nitric oxide184 . 
Homocysteine has also been found to promote vascular smooth muscle cells hypertrophy; 
Tsai et al (1994) 185 performed an in vitro study examining the effect of homocysteine on 
the growth of both vascular smooth muscle cells and endothelial cells at concentrations 
similar to those observed clinically. The presence of as little as 0.1 mM homocysteine 
caused a 25% increase in DNA synthesis, and homocysteine at 1 mM increased DNA 
synthesis by 4.5-fold in rat aortic smooth muscle cells. In contrast, they found that 
homocysteine caused a dose-dependent decrease in DNA synthesis in human umbilical 
vein endothelial cells. It was also observed that homocysteine increased mRNA levels of 
cyclin D1 and cyclin A in aortic smooth muscle cells by 3- and 15-fold, respectively, 
indicating that homocysteine induced the mRNA of cyclins important for the re-entry of 
quiescent smooth muscle cells into the cell cycle 185 . The growth-promoting effect of 
homocysteine on vascular smooth muscle cells, together with its inhibitory effect on 
endothelial cell growth186, may explain homocysteine-induced atherosclerosis. 
1.4.2.1 5, 10- Methylenetetrahydrofolate Reductase 
The enzyme 5, 10-Methylenetetrahydrofolate reductase (MTHFR) catalyzes the 
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reduction of 5, 10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, the 
predominant circulatory form of folate and carbon donor for the re-methylation of 
homocysteine to methionine. A loss of function in this enzyme would result in an 
accumulation of homocysteine. Frosst et al (1995) identified a common polymorphism in 
MTHFR which alters a highly-conserved amino acid; the substitution (C677T) occurs at a 
frequency of approximately 38% of unselected chromosomes and occurs within the 
predicted catalytic domain of the MTHFR enzyme187 . This gene variation in either 
heterozygotes or homozygotes was shown to be associated with reduced enzyme activity 
and increased thermo lability in lymphocyte extracts; in vitro expression of the 677T allele 
confirmed its effect on thermolability of MTHFR. Individuals homozygous for the 
mutation were found to have significantly elevated plasma homocysteine levels. Several 
studies conducted since this polymorphism was identified have confirmed an association 
between MTHFR 677T and both premature cardiovascular disease188'190 and coronary 
artery disease191 . Klujitmans et al. found that homozygosity for the 677T allele was found 
in 9 of 60 (15%) cardiovascular patients and in only 6 of 111 (5%) control individuals 
from the Netherlands (OR 3.1, 95% CI: 1.0-9.2)188 . Mager et al. showed that the 
prevalence of homozygosity for the 677T allele among Israeli patients with early CAD 
onset (aged< or= 45 years) was 28%, (n=67) which was significantly higher than that in 
patients with later onset (13%, n=102) and in control subjects (14%, n=313) (OR 2.4, 
95% CI 1.24-4.69, p=0.006, and OR 2.7, 95% CI 1.15-6.42, p=0.01, respectively) 189 . 
Morita et al. observed that in 778 healthy male Japanese subjects, the frequency of the 
677T allele was 0.33, whereas In 362 patients with CAD, the TT genotype was 
significantly more frequent than in control subjects (16% versus 10%, P=.0067). The 
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association of the TT genotype with CAD was further increased in patients with ~> or = 
99% stenotic lesions (18%, P=.OOl 0), whereas no significant association with the TT 
genotype was observed in patients without a stenosis. When the genotype frequency was 
compared among patients with different numbers of stenotic coronary arteries, the 
frequency of the TT genotype was significantly higher in patients with triple-vessel 
disease (26%) than in patients with single- or double-vessel disease (15% and 14%, 
respectively: ?<.0001) 190 . Van Bockxmeer et al. did not, however, find such a 
relationship in their study of 555 white Western Australians with angiographically 
documented coronary artery disease and 143 unrelated controls191 . 
Van der Put et al192 identified another polymorphism of the MTHFR gene: This 
DNA sequence change, an A>C transition at nucleotide 1298 results in a glutamic acid-
to-alanine substitution at amino acid residue 429 (E429A), and had an allele frequency of 
0.33. The 1298 A-C transition is located in the presumed regulatory domain and is 
associated with decreased MTHFR activity, which was more pronounced in the 
homozygous than heterozygous state192 . Despite the lower activity of the enzyme variant, 
neither the homozygous nor the heterozygous state was associated with higher plasma 
homocysteine or a lower plasma folate concentration - phenomena that are evident with 
homozygosity for the 677C-T mutation. 
While the A1298C variant does not appear to raise homocysteine levels, some 
evidence does nonetheless indicate an association with coronary artery disease. Szczeklik 
et al (2001) 193 found that the prevalence of the 1298C allele was significantly higher in 
CAD patients (n=l61 men) compared to control subjects with no history or evidence of 
CAD (n=211) (0.304 vs. 0.199, p=O.OOl) or from a random population sample or 
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residents of downtown Cracow, Poland (n=31 0) (0.304 vs. 0.235 p=0.003). The 1298C 
allele showed a significant association with early-onset CAD both in homozygotes and in 
heterozygous carriers despite the fact that there was no observed difference in fasting 
plasma homocysteine, folic acid and vitamin B12 levels between CAD patients and 
controls. The possibility of a founder effect explaining the two common MTHFR 
polymorphisms has been postulated due the short molecular distance of 2100 base pairs 
between the two polymorphisms, however this explanation has been discounted as no 
alleles sharing both the 677T and 1298C nucleotides have been identified192•194 . The 
MTHFR A1298C polymorphism remains a valid potential risk factor for cardiovascular 
disease and MI. 
1.5 Rationale and Goals for Current Study. 
As described above, a large number of studies have been done on several different 
ethnic populations from different locations around the world attempting to correlate 
variations of the genes coding for proteins within the blood coagulation pathway to the 
clinical outcome of arterial thrombosis, including MI. These studies have frequently 
produced conflicting results, due to such features as relatively small sample sizes, a low 
frequency of the gene variant being investigated, and ethnic heterogeneity of the 
populations being investigated. 
As MI is a multifactorial disorder, the genetic component in MI may be the result 
of a combined effect of a number of genes, with each playing only a small role. The 
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predisposition imparted by individual genes may act independently or interact with other 
genes to result in an additive effect and/or synergistic co-effect. One of the largest and 
most common challenges facing case control studies on possible gene-gene interactions is 
the ethnic heterogeneity of the investigated populations. Newfoundland presents an 
interesting and unique population structure which can help to overcome the heterogeneity 
frequently found in other studies. 
The island portion of the Canadian province of Newfoundland and Labrador is 
located in the Atlantic Ocean, off the eastern coast of Canada. The population of the 
island of Newfoundland consists mainly of descendants of English and Irish settlers who 
arrived in the late 18th and early 19th centuries195 . The settling of Newfoundland is 
somewhat unique when compared to colonization of other areas of the New World, as the 
majority of those who immigrated to Newfoundland can be traced almost exclusively 
back to small regions in southwest England (the neighbouring counties of Cornwall, 
Devon, Somerset, Dorset, and Hampshire) and southeast Ireland (roughly a 30 mile radius 
from the city of Waterford). These areas were the principal ports ofthe United Kingdom's 
fishing industry at the time 196. The major migrations concluded in the mid-19th century at 
which point the population of the island was approximately 75, 000 individuals. From this 
limited number of founding individuals, the population grew almost exclusively through 
expansion as the geographical and social isolation of this island has ensured very little 
inward migration for several hundred years197 and thus has lead to a small population (530 
000 individuals; Statistics Canada 2001 -50% of whom still live in communities smaller 
than 2500 individuals 197) with a relatively homogenous genetic background ideal for the 
study of complex multifactorial disease such as MI. 
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In order to overcome the described weaknesses that are commonly faced, we 
simultaneously analyzed the frequency of FVL, FIIG20210A, FXIII-A V34L, FVII 
R353Q, MTHFR A1298C and Il-6 -174 G/C in 500 biochemically verified MI patients 
and 500 healthy individuals in the genetically isolated Newfoundland population in order 
to determine the individual and combined influence of these gene variants on the 
occurrence of MI. 
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MATERIALS AND METHODS 
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2.1 Ascertainment and Clinical Analysis of Myocardial Infarction Patients and 
Control Subjects 
Whole blood samples were collected from 500 consecuitive MI patients and 500 
healthy controls from the genetically isolated Newfoundland population. Patients 
categorized in the MI group represented those presenting to the emergency department or 
within one of the Health Care Corporation of St. John's hospitals with symptoms and 
biochemical evidence suggestive of MI. Only patients with cardiac Troponin I values that 
were greater than 2.0 )lg/L (Axsym, Abbott Diagnostics) 198, or greater than 0.5 )lg/L 
(Access II, Beckman-Coulter Corp) 199 were used in this group. Control subjects were 
selected from consecutive individuals without prior history of MI or thrombosis 
presenting to the emergency department for trauma, accidental injury, or other non-
cardiac and non-thrombotic related events. Discarded blood samples collected for 
complete blood count were used for DNA extraction and analysis. Upon collection the 
sample was entered into a computerized database, for the purpose of holding such 
information as a patient's age and gender, as well as details of the biochemical evidence 
of their MI in the case of MI patient subjects. Each sample was then given a unique 
identifying number to correspond with this data and all further information regarding a 
patients' identity was then destroyed. All subjects, both MI patients and healthy controls 
were identified only by their unique case number for the entire duration of this project. 
A protocol for clinical investigation for this study was granted ethical approval by 
the Human Investigations Committee of the Faculty of Medicine, Memorial University of 
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Newfoundland, and by the Health Care Corporation of St. John's. 
2.2 DNA Extraction From Whole Blood 
All DNA samples were extracted from white blood cells of venous blood which 
was collected from subjects in EDTA vacutainer tubes. DNA extraction was performed 
using a protocol based on a simple salting-out method described by Miller et al. 200 with 
the following modifications: 5ml of whole blood was first transferred to a 15ml centrifuge 
tube. 5 ml ofTKM1 buffer (10 mM Tris, 10 mM KCL, 10 mM MgCh, 2 mM EDTA) was 
then added to the blood, followed by 1.25 ml of a membrane-lysing agent, 10% Igepal 
(Sigma - a non-ionic detergent; Octylphenyl-polyethylene glycol). These components 
were then mixed by inversion several times, and centrifuged at 2200 rpm (1400 G) for ten 
minutes at room temperature. The supernatant was then poured off and the nuclear pellet 
was saved, washed with a further 10 ml of TKM1 buffer, and centrifuged at 2200rpm for 
ten minutes at room temperature once more. Following this centrifugation, the supernatant 
was once again poured off, and the nuclear pellet was re-suspended in 0.8 ml of TKM2 
buffer (10 mM Tris, 10 mM KCL, 10 mM MgCb, 2 mM EDTA, 0.4 M NaCl). This 
mixture was then transferred to a 1.5 ml microfuge tube containing 50 ~Ll of 10% SDS, 
mixed well, and incubated for 30 minutes in 50°C water bath. Following this incubation, 
0.4 ml of 5M NaCl was added to the tube, mixed, and then centrifuged at 12000 rpm 
(30000 G) in a microfuge. The supernatant from this centrifugation was saved, transferred 
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to a clear 15 ml centrifuge tube to which 2.4ml of absolute ethanol was added. The tube 
was then closed and gently inverted several times while the DNA precipitated. A 9" glass 
pipette was melted into a hook and cooled prior to the beginning of the extraction 
procedure, and was then used to remove the DNA from the tube. The hook was then 
inverted and allowed to dry for one to two minutes and then re-dissolved in 100-200 )ll of 
either TE buffer (10 mM Tris, 1 mM EDTA, pH 8) or ultra-pure deionized water. 
2.3 Genotyping 
All alleles were amplified v1a the polymerase chain reaction (PCR) usmg 
approximately 100 - 200 ng of template DNA from the acquired MI patients and healthy 
control subjects. All primers used were purchased from Integrated DNA Technologies Inc 
(Coralville, Iowa, USA). Amplification for was carried out using a standard 50 )ll PCR 
reaction containing 2.5 )lMol of each primer, as well as 125 )lM dNTPs, GeneAmp 1 OX 
PCR Buffer consisting at final reaction concentrations of 15 mM MgCh 10 mM KCl, 10 
mM (NH4) 2S04, 20 mM Tris-HCl, 2 mM MgS04, 0.1% Triton X-1 00, pH 8.8@ 25°C, and 
2.5 units of AmpliTaq DNA polymerase (All dNTPs, PCR buffer and polymerase were 
purchased from Applied Biosystems Foster City, California, USA). Thermocyclers used 
for all amplification reactions were the PerkinElmer Gene-Amp 9600 (PerkinElmer, 
Boston, Massachusetts, USA) and the Eppendorf MasterCycler (Eppendorf AG, 
Hamburg, Germany). All restriction endonucleases and buffers used were purchased from 
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New England Bio Labs, Beverly, Massachusetts, USA. 
2.3.1 Factor V Leiden and Prothrombin G20210A 
The Factor V and Prothrombin alleles were amplified simultaneously in a 
multiplex PCR reaction. The Factor V allele was amplified using the primers 5' - ACC 
CAC AGA AAA TGA TGC CCA - 3' (forward) and 5'- TGC CCC ATT ATT TAG 
CCA GGA - 3' (reverse) creating a 224bp DNA fragment. The Prothrombin allele was 
amplified using the primers 5'- TCT AGA AAC AGT TGC CTG GC- 3' and 5'- ATA 
GCA CTG GGA GCA TTG AGC- 3' creating a 345bp DNA fragment. All samples were 
amplified by using a denaturing of 5 minutes at 94°C, followed by 35 cycles of 40 
seconds at 94°C, 40 seconds at 55°C, and 1 minute at 72°C, with a final extension of 5 
minutes at 72°C. Following amplification of these alleles, all PCR products were digested 
with 10 units each of the restriction endonucleases Hindiii and Mnli in the restriction 
buffer NEB2 (50 mM NaCl, 10 mM Tris-HCl, 10 mM MgCh, 1 mM dithiothreitol, pH 
7.9 @ 25°C) for four hours at 37°C. When present, the G>A transition at nucleotide 
20210 of the Prothrombin gene creates a sequence of 5'-AGCTT-3' that is recognized by 
the Hindiii enzyme. In the case of the G>A transition at nucleotide1691 of the Factor V 
Leiden polymorphism, a sequence of 5'-GAGG-3' which is recognized by the Mnli 
enzyme is obliterated. The wild-type FII fragment contains two Mnl I sites but no Hindiii 
sites, resulting in fragments of 15, 58, and 272 bp, whereas the 20210A (mutated) product 
contains two Mnl I sites and one Hindiii site, resulting in fragments of 15, 23, 58, and 
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249 bp after double digestion. The FV fragment contains no Hindiii sites, resulting in Mnl 
I fragments of 37, 67, and 116 bp for the wild-type allele and 67 and 153 bp for the 
mutated allele. Consequently, when both PCR products of a patient double heterozygote 
for FII and FV are digested, fragments of 272, 249, 153, and 116 bp are detected by 
performing gel electrophoresis on the digested PCR products by running them through 
10% polyacrylamide for 220 minutes at 1 OOv, and then staining with ethidium bromide in 
order to visualize the location of the DNA within the gels. The presence of bands of the 
appropriate length confirmed the presence of the polymorphism in both genes. 
2.3.2 Factor XIII-A Val34Leu 
Exon 2 of the Factor XIII-A allele was amplified using the primers 5'-CAT GCC 
TTT TCT GTT GTC TTC- 3' (forward) and 5'- TAC CTT GCA GGT TGA CGC CCC 
GGG GCACTA - 3' (reverse) creating a 192 bp DNA fragment. All samples were 
amplified by using a denaturing of 2 minutes at 94°C, followed by 35 cycles of 30 
seconds at 94°C, 30 seconds at 48°C, and 1 minute at 72°C, with a final extension of 7 
minutes at 72°C. Following amplification for this allele, all samples were digested with 10 
units of the restriction endonuclease Ddei in the restriction buffer NEB3 (1 00 mM N aCl, 
50 mM Tris-HCl, 10 mM MgCh, 1 mM dithiothreitol, pH 7.9@ 25°C) for four hours at 
37°C. When present, the G >T missense mutation in the 34th amino acid residue of the 
Factor XIII-A subunit, creates a sequence of 5'- C''TNAG- 3' which is recognized by the 
Ddei enzyme resulting in two fragments of 161 bp and 31 bp in length. The presence or 
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absence of this polymorphism was then analyzed by performing gel electrophoresis on the 
digested PCR products by running them through 10% polyacrylamide for 220 minutes at 
100v, and then staining with ethidium bromide. 
2.3.3 Factor VII R353Q 
The Factor VII allele was amplified using the primers 5'- TGA TGA CCC AGG 
ACT GCC T - 3' (forward) and 5' - GGG ATT TGG TGC CAG GAC A - 3' (reverse) 
creating a 372 bp DNA fragment. All samples were amplified by using a denaturing of 7 
minutes at 94°C, followed by 35 cycles of 30 seconds at 92°C, 30 seconds at 60°C, and 45 
seconds at 70°C, with a final extension of 7 minutes at 70°C. Following amplification for 
this allele, all samples were digested with 10 units of the restriction endonuclease Mspl in 
the restriction buffer NEB2 (50 mM NaCl, 10 mM Tris-HCl, 10 mM MgClz, 1 mM 
dithiothreitol, pH 7.9 @ 25°C) for four hours at 37°C. When present, the A>C transition 
in the gth exon of the Factor VII gene causes a substitution of a glutamine residue instead 
of the arginine which is normally found at 353rd amino acid residue. This substitution 
creates a sequence of 5'- C'"'CGG - 3' that is recognized by the Ddel enzyme which then 
cleaves the PCR product resulting in two fragments of 227 bp and 145 bp in length. The 
presence or absence of this polymorphism was then analyzed by performing gel 
electrophoresis on the digested PCR products by running them through 2% agarose for 35 
minutes at 200v, and then staining with ethidium bromide. 
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2.3.4 MTHFR A1298C 
The A1298C polymorphism in exon 7 of the MTHFR gene was amplified using 
the primers 5'- CTT TGG GGA GCT GAA GGA CTA CTA C- 3' (forward) and 5'-
CAC TTT GTG ACC ATT CCG GTT TG- 3' (reverse) creating a 163 bp DNA fragment. 
All samples were amplified by using a denaturing of 2 minutes at 92°C, followed by 3 5 
cycles of 1 minute at 92°C, 1 minute at 51 °C, and 3 0 seconds at 72°C, with a final 
extension of 7 minutes at 72°C. Following amplification for this allele, all samples were 
digested with 10 units of the restriction endonuclease Mboll in the restriction buffer 
NEB2 (50 mM NaCl, 10 mM Tris-HCl, 10 mM MgCb, 1 mM dithiothreitol, pH 7.9 @ 
25°C) for four hours at 37°C. When present, this A>C substitution causes a glutamine ---+ 
alanine substitution at the 4291h amino acid residue. This substitution creates a sequence 
of 5'- GAAGA(N)8 - 3' that is recognized by the Mboll enzyme which then cleaves the 
PCR product resulting in five fragments of 56, 31, 30, 28, and 18 bp if the mutation is 
present and four fragments of 84, 31, 30, and 18 bp in length if the mutation is absent. 
The presence or absence of this polymorphism was then analyzed by performing gel 
electrophoresis on the digested PCR products by running them through 12% 
polyacylramide for 75 minutes at 1 OOv, and then staining with ethidium bromide. 
2.3.5 11-6 -174G/C 
The -174 G/C polymorphism in the promoter region of the Il-6 gene was amplified 
using the primers 5'- TGC GAT GGA GTC AGA GGA AAC TCA- 3' (forward) and 5'-
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AGC CTC AGA CAT CTC CAG TCC TAT - 3' (reverse) creating a 492 bp DNA 
fragment . All samples were amplified by using a denaturing of 5 minutes at 94 °C, 
followed by 35 cycles of 45 seconds at 94°C, 30 seconds at 54°C, and 1 minute at 72°C, 
with a final extension of 7 minutes at 72°C . Following amplification for this allele, all 
samples were digested with 10 units of the restriction endonuclease Nlaiii in the 
restriction buffer NEB4 (50 mM potassium acetate, 20 mM Iris-acetate, 10 mM 
magnesium acetate, 1 mM dithiothreitol , pH 7.9 @ 25°C. Supplement with 100 f!g/ml 
BSA) for four hours at 3 7°C). When present, this G>C substitution in the promoter creates 
a sequence of 5' -CAGT- 3' that is recognized by the Nlaiii enzyme which then cleaves 
the PCR product resulting in five fragments of 172, 122, 111, 58 and 29 bp if the 
mutation is present and four fragments of233, 172, 58, and 29 bp in length ifthe mutation 
is absent. The presence or absence of this polymorphism was then analyzed by 
performing gel electrophoresis on the digested PCR products by running them through 
3.5% agarose for 35 minutes at 200v, and then staining with ethidium bromide. 
2.4 Statistical Analysis 
The prevalence of each gene variant was calculated by counting the total carrier 
frequency including heterozygotes and homozygotes. The allele frequencies were 
determined by gene counting. Gene-gene interactions were determined by 1) comparing 
the prevalence of combined carrier for multiple gene variants in patients and controls; 2) 
analysis of the distribution of one chosen gene variant in sub-grouped patients and 
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controls who carry another gene variant as genetic background. Pearson Chi-square 
statistical analysis was performed to test the association between each genotype and the 
prevalence of MI. A multivariate analysis using logistic regression was also employed in 
the analysis in order examine the effect of several variables (genotypes) upon the outcome 
(presence or absence of aMI event). Odds ratios (OR) were calculated as a measure of the 
relative risk for MI and were given with 95% Cis. All statistical calculations were 
performed using SPSS vl 0.0 (SPSS Inc., Chicago, IL, USA). 
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The gene variants, Factor V Leiden (FVL) and prothrombin G20210A 
(FIIG2021 OA) are the two most commonly recognized genetic prothrombotic risk factors 
for venous thrombosis60•70 ·201 '202 . In contrast, a gene variant of factor XIII, FXIIIV34 L, has 
recently been reported to confer protection against arterial116-118 ' and venous 
thrombosis 114' 115 . In most Caucasian populations, the prevalence of FVL and FIIG2021 OA 
approximates 6%, and 2%, respectivel/0•201 '202 . World wide heterogeneous geographic 
and ethnic distributions for FVL and FIIG2021 OA have been suggested by certain 
studies41 •43 ,47,203 . Although a low prevalence of these two gene variants has been reported 
in Asian populations by a few initial surveys, the small sample sizes from most of these 
studied populations have made it impossible to determine the prevalence of these gene 
variants. The FXIIIV34L shows a prevalence of 45% (allele frequency of 26%) among 
Caucasians116•204, however the prevalence of this gene variant in Asian populations is 
unknown. 
To determine the prevalence of FVL, FIIG2021 OA and FXIIIV34L in the Chinese 
population we analyzed DNA samples from 500 unrelated, healthy women from the 
Taiwan area of China. All of these blood samples were previously collected as normal 
controls for another research project. Genomic DNA was extracted using the standard 
salting out procedure200 . Genotyping analyses of the FVL, FIIG20210A and FXIIIV34L 
variants were determined using previous I y described methods 116•205 •206 . The allele 
frequency in different ethnic populations was compared using the Chi-square test. 
The carrier frequencies, allele frequencies, and genotypes of FVL, FIIG2021 OA 
and FXIIIV34L from the 500 Chinese are given in Table 1. Data from 500 healthy, 
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unrelated individuals from the Newfoundland Caucasian population is also included in the 
Table. All subjects from the Newfoundland population were normal controls used in 
another on going project (Butt et al., in preparation). Newfoundland is geographically 
isolated from the rest of Canada with the majority of the population being of English and 
Irish descent. This has provided a relatively homogeneous genetic background. 
Consistent with other Caucasian populations, the prevalence of FXIIIV34L and 
FVL in the Newfoundland population are 52.2% and 4.6%, which yields allele frequencies 
of 27.1% and 2.3%, respectively. However, the prevalence of 1.0% for FIIG20210A 
(giving a 0.5% allele frequency) among Newfoundlanders is lower than the 2% commonly 
reported for most Caucasian populations. Of great interest is the extremely low prevalence 
of all of these variants in Chinese. Among the 500 Chinese individuals, only one 
heterozygote for each of the three gene variants was detected. No homozygotes or 
combined heterozygotes were found. The prevalence and allele frequency were 0.2% and 
0.1 %, respectively, for all of the three variants in the Chinese population. This 
demonstrates a large and significant difference in the allele frequencies for the FVL 
(P<O.OOl) and FXIIIV34L (P<O.OOl) in the Chinese population compared with our 
Caucasian controls. The allele frequency of FIIG2021 OA was also lower but did not 
achieve statistical significance. 
To the best of our knowledge, the present study is the first to establish the 
prevalence of FXIIIV34L in the Chinese population. These results also show a significant 
and highly heterogeneous and ethnic-dependent distribution of FVL, and FXIIIV34L 
variants between Chinese and Caucasian populations. The Chinese population has a 5-fold 
lower prevalence ofFIIG20210A, a 23-fold lower prevalence ofFVL and 240-fold lower 
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prevalence ofFXIII34L compared with our Caucasian controls. Compared with the results 
of preliminary surveys on other Asian populations, our results suggest that the Chinese 
population have the lowest frequencies of these gene variants studied so far. The 
dramatically lower prevalence of FVL and FIIG2021 OA in the Chinese population 
suggests a less significant role in predisposing Chinese to venous thrombosis. Recognition 
of this in the North American Chinese population will be of clinical significance for proper 
clinical evaluation of thrombotic risk for ethnic Chinese patients. Furthermore, the 
dramatically lower prevalence of FXIIIV34L in Chinese suggests that this gene variant 
might not be a useful candidate allele for further study of arterial thrombosis in Chinese. 
Table 3.1: Carrier frequencies, allele frequencies, and the frequencies for genotypes 
ofFVL, FIIG20210A and FXIIIV34L in Chinese and Newfoundland Caucasians 
Genotype Chinese (n = 500) Newfoundlanders (n = 500) 
VN 499 (99.8%) 261 (52.2%) 
FXIIIV34L VIL 1 (0.2%) 207 (41.4%) 
LIL 0 (0%) 32 (6.4%) 
Carrier frequency 0.2% 47.8% 
Allele frequency of L 0.1% 27.1% 
GIG 499 (99.8%) 495 (98.9%) 
FIIG20210A GIA 1 (0.2%) 5 (1.0%) 
AlA 0 (0%) 0 (0%) 
Carrier frequency 0.2% 1.0% 
Allele frequency of A 0.1% 0.5% 
GIG 499 (99.8%) 477 (95.4%) 
FVL GIA 1 (0.2%) 23 (4.6%) 
AlA 0 (0%) 0 (0%) 
Carrier frequency 0.2% 4.6% 
Allele frequency of A 0.1% 2.3% 
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Abstract 
Studies associating prothrombin G2021 OA (FIIG2021 OA), Factor V Lei den 
(FVL), and Factor XIIIV34L (FXIII-A V34L) with myocardial infarction (MI) have 
yielded conflicting results. Complicated gene-gene interactions, small sample sizes and 
heterogeneous genetic and environmental backgrounds may contribute to conflicting 
results. Simultaneous analysis of multiple gene variants in a large sample size from a 
genetically isolated population may overcome these weaknesses. Genotyping was 
performed in 500 MI patients and 500 controls from the genetically isolated 
Newfoundland population to determine the prevalence ofFIIG20210A, FVL and FXIII-A 
V34L variants and association with MI. Gene-gene interactions were also analyzed. The 
prevalence of FIIG20210A was higher in MI patients (3.2%) than in controls (1.0%; 
P=0.015). FIIG20210A was also 5.6 fold higher in MI patients younger than 51 years 
compared with age-matched controls (P=0.04). FVL showed 3.9-fold higher prevalence 
in young patients than older (>50 years) patients (P = 0.004), and 2.7-fold higher than 
age-matched controls (P =0.007). Furthermore, the prevalence of combined carriers of 
FXIII-A V34L and FIIG20210A alleles was 12-fold higher in MI patients compared with 
controls (P = 0.002) and with 92% penetrance. There was disequilibrium of FXIII-A 
V34L allele to MI patients carrying FIIG2021 OA as a genetic background. Based on our 
data, 1) FIIG2021 OA is a risk factor for MI, possibly important for early onset; 2) FVL 
may predispose for early onset MI; 3) FXIII-A V34L predisposes for MI in males only; 
however, 4) interaction between FIIG20210A and FXIII-A V34L form a synergistic co-
effect which strongly predisposes for MI, placing combined carriers at high risk for MI. 
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Introduction 
The pathogenesis of myocardial infarction (MI) involves an interaction between 
environmental influences and genetic predisposition. Genetic factors involving blood 
coagulation may contribute to the pathogenesis of atherosclerosis as well as play a role in 
the clinical progression to plaque rupture and localized occlusive thrombus formation207 . 
The gene variants Factor V Leiden (FVL-R506Q) and prothrombin G20210A 
(FIIG2021 OA) are the two most commonly recognized genetic prothrombotic risk factors 
for venous thrombosis60 '70 '201 '202 . Based on the increased thrombotic tendency in venous 
thrombosis studies, these two gene variants have also been examined for possible 
association with arterial thrombosis in MI. Several studies have shown a higher 
prevalence of FIIG20210A in patients with MI compared to normal controls72 •89-91 . 
However, most of the results from these studies failed to achieve statistical significance, 
possibly because of the extremely low frequency of FIIG2021 OA in the studied 
population and the use of relatively small sample sizes. Nevertheless, a few studies have 
presented conflicting results 73 '81 . Although FVL strongly correlates with deep venous 
thrombosis (DVT), the majority of the previous studies have failed to show a correlation 
between FVL and MI54 '61 '84 . Recently, a few studies have suggested that FVL may 
associate with early onset MI64 '208 and MI with normal coronary angiographl6. In 
contrast, a common gene variant, factor FXIII-A V34L (FXIIIV34L) has recently been 
suggested to confer a protective role against MI based on a lower prevalence of FXIII-A 
V34L in MI patients compared with controls116-118 . However, conflicting results were also 
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reported209-211 . Furthermore, results from function studies on the FXIII-A V34L allele do 
not support the hypothesis of a protective role against MI112 '204 . Therefore, the role of 
these three gene variants in the pathogenesis ofMI remains unknown. 
Being a multifactorial disorder, the genetic components in MI may be a combined 
effect of a number of genes with each playing only a small role. The predisposition 
imparted by individual genes may act independently or interact with other gene (genes) to 
result in an additive effect and/or synergistic co-effect. Common challenges facing case 
control studies on possible gene-gene interactions include relatively small sample sizes, a 
low frequency of gene variants, and ethnic heterogeneity of the investigated populations. 
To overcome these weaknesses, we simultaneously analyzed FVL, FIIG20210A, and 
FXIII-A V34L in 500 MI patients and 500 normal individuals of the genetically isolated 
Newfoundland population. 
The island portion of the Canadian province of Newfoundland and Labrador is 
located in the Atlantic Ocean, off the eastern coast of Canada. The population of the 
island of Newfoundland consists mainly of descendants of English and Irish settlers who 
arrived in the 18th and 19th centuries 196 . The geographical and social isolation of this 
island has ensured very little inward migration for several hundred years197 and thus has 
lead to a small population (530 000 individuals; Statistics Canada 2001) with a relatively 
homogenous genetic background ideal for the study of complex multifactorial disease 
such as MI. 
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Our analysis not only attempted to correlate MI with each of the three gene 
variants but also examined for possible gene-gene interactions among the three gene 
variants in MI. High allele frequency of FXIII-A V34L in both MI patients and normal 
populations permits us to determine the distribution of co-existence of the FXIII-A V34L 
and either FIIG2021 OA or FVL in both MI patient and control populations. 
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Materials and Methods 
Subjects: 
Blood samples were collected from 500 consecuitive MI patients (221 males and 
279 females) and 500 normal controls (214 males and 286 females) of the genetically 
isolated Newfoundland population. Patients categorized in the MI group represented 
those presenting to the emergency department or within one of the Health Care 
Corporation of St. John's hospitals with symptoms and biochemical evidence suggestive 
of MI. Only patients with cardiac Troponin I values greater than 2.0 !Jg/L (Axsym, 
Abbott Diagnostics) 198 or greater than 0.5 !Jg/L (Access II, Beckman-Coulter Corp.)199 
were used in this group. Control subjects were selected from consecutive individuals 
without prior history of MI or thrombosis presenting to the emergency department for 
trauma, accidental injury, or other non-cardiac and non-thrombotic related events. 
Discarded blood samples collected for complete blood count were used for DNA 
extraction and analysis. Ethics approval for this study was granted by the Human 
Investigation Committee of Memorial University and by the Health Care Corporation of 
St. John's. 
Genotyping ofFII20210A, FVL and FXIII-A V34L: 
Genomic DNA was isolated from the peripheral blood using standard methods200 . 
Genotyping of the FVL, FIIG20210A and FXIII-A V34L were performed by PCR 
amplification of each of the target alleles from genomic DNA followed by restriction 
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digestion with each of corresponding enzymes Mnll, Hindiii and Ddel, respectively, as 
previously described 112 '206 . The digested PCR products were separated by electrophoresis 
in 10% polyacrylamide gels and visualized by staining with ethidium bromide. 
Prevalence determination and association study: 
The prevalence of each gene variant was calculated by counting the total carrier 
frequency including heterozygotes and homozygotes. The allele frequencies were 
determined by gene counting. Pearson Chi Square statistical analysis was performed 
using SPSS vl 0.0 to test the association between genotypes and the prevalence of MI. 
Odds ratios (OR) were calculated as a measure of the relative risk for MI and were given 
with 95% Cis. 
Analysis of gene-gene interaction: 
Gene-gene interactions were determined by 1) companng the prevalence of 
combined carrier for two of the three gene variants in patients and controls; 2) analysis of 
the distribution of one chosen gene variant in sub-grouped patients and controls who 
carry another gene variant as genetic background. 
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RESULTS 
Genotyping FIIG20210A, FVL and FXIII-A V34L: 
The genotype distributions, carrier frequencies, and allele frequencies of 
FIIG20210A, FVL, and FXIII-A V34L in both the MI patient and the control populations 
are given in Table 4.1. The FIIG2021 OA allele was detected in 3.2% of patients which 
was significantly higher than the 1% observed in controls (OR 3.2, 95% CI 2.6-4.0, P = 
0.015). An identical prevalence of FVL was observed in both patient and control 
populations (4.6% vs. 4.6%). No homozygotes for either FIIG20210A or FVL allele were 
found in either population. In both patient and control populations, FXIII-A V34L had 
similar prevalence (47.0% vs. 47.8%) and allele frequency (27.7% vs. 27.1 %). The 
prevalence of homozygous 34L was higher in patients compared with controls (8.4% vs. 
6.4%), but the difference did not reach statistical significance. 
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Table 4.1: Distributions of genotypes, and carrier and allele frequencies of 
FIIG20210A, FVL and FXIII-A V34L in MI patient and healthy control (HC) 
populations. 
Genotype MI (n = 500) HC (n = 500) OR P value 
GIG 484 (96.8%) 495 (99.0%) 
FIIG20210A G/A 16 (3.2%) 5 (1.0%) 
AlA 0 (0%) 0 (0%) 
Carrier F. 3.2% 1.0% 3.2 0.015 
Allele F. 1.6% 0.5% 
R/R 477 (95.4%) 477 (95.4%) 
FVL(R506Q) R/Q 23 (4.6%) 23 (4.6%) 
Q/Q 0 (0%) 0 (0%) 
Carrier F. 4.6% 4.6% 1.00 NS 
Allele F. 2.3% 2.3% 
V/V 265 (53.0%) 261 (52.2%) 
FXIII-A V34L V/L 193 (38.6%) 207 (41.4%) 
LIL 42 (8.4%) 32 (6.4%) 
Carrier F. 47.0% 47.8% 0.97 NS 
Allele F. 27.7% 27.1% 
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The distribution of the three gene variations was further analyzed by sub-grouping 
patients and controls according to age (Table 4.2). MI patients were divided into those 
with an early age of onset (:S 50 years) and those with a later age of onset (>50 years). 
The control population was also divided into the two corresponding age groups. 
Interestingly, a disequilibrium distribution of the FVL allele was observed in the early 
onset patient group. The FVL allele was detected in 13.0% of patients with early age of 
onset, which was significantly higher than the 3.8% in patients with a later age of onset 
(OR: 3.9, 95% CI 3.3-4.4; P = 0.004) and the 4.8% in the age matched controls (OR: 3.0, 
95% CI 2.2-3.7; P= 0.007). The prevalence ofFII 20210A was also significantly higher in 
the early onset group of MI (4.3%) compared to the controls under age 50 (0.8%). 
Although the prevalence of FII G2021 OA was slightly higher in the early onset group 
compared to the later onset group, this difference did not achieve statistical significance. 
The FXIII-A V34L allele showed a slight but statistically insignificant difference in 
prevalence between the patients with early and later onset age. 
The distribution of the three gene variations was further analyzed by sub-grouping 
patients and controls based on gender (Table 4.3). The gender ratio in both the 500 MI 
patients and 500 controls were similar. The distribution of the three gene variations in 
controls showed no significant difference between males and females. However, there 
were significant differences in the distribution of FVL and FXIII-A V34L between sexes 
in MI patients. The prevalence of both FVL and FXIII-A V34L was significantly higher 
in males than in female patients. The prevalence of FIIG2021 OA was not significantly 
different between sexes among MI patients. 
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Table 4.2: Distribution of genotypes among MI patients with different onset ages 
and compared with age-matched healthy controls (HC). 
MI HC OR p 
FII 20210A Carriers 16/500 (3.2%) 5/500 (1 %) 3.3 0.015 
Age :5 SOY 2/46 (4.3%) 3/373 (0.8%) 5.6 0.04 
Age> SOY 14/454 (3.1 %) 2/127 (1.6%) 2.0 NS 
FVL Carriers 23/500 (4.6%) 23/500 (4.6%) 1.0 NS 
Age :5 SOY 6/46 (13.0%) 18/373 (4.8%) 3.0 0.007 
Age> SOY 17/454 (3.8%) 51127 (3.9%) 1.0 NS 
FXIII 34LCarriers 235/500 (47.0%) 239/500 (47.8%) 1.0 NS 
Age :5 SOY 19/46 (41.3%) 176/373 (47.2%) 0.8 NS 
Age> SOY 216/454 (47.6%) 63/127 (49.6%) 0.9 NS 
Table 4.3: Comparison of genotypes distribution in different genders among MI 
patients and healthy controls 
Males Females OR (95% CI) p 
FII20210A 
MI 8/221 (3.6%) 8 /279 (2.9%) 1.3 (0.5, 3.5) 0.635 
HC 3/214 (1.4%) 2/286 (0.7%) 2.0 (0.3, 12.2) 0.435 
FVL 
MI 16/221 (7.2%) 7/279 (2.5%) 3.0 (1.2, 7.5) 0.012 
HC 8/214 (3.7%) 15/286 (5.2%) 0.7 (0.3, 1.7) 0.426 
FXIII-A V34L 
MI 140/221 (63.3%) 95/279 (34.1 %) 3.3 (2.3, 4.8) <0.001 
HC 97/214 (45.3%) 110/286 (38.5%) 1.3 (0.9, 1.9) 0.123 
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Gene-gene Interactions: 
FIIG20210A and FXIII-A V34L: 
Interaction between FXIII-A V34L and FIIG20210A was first analyzed by 
comparing the prevalence of combined carriers (individuals carrying both FIIG2021 OA 
and FXIII-A V34L) in the total patient and control populations with their corresponding 
theoretical prevalence of combined carriers. Using carrier frequencies described in table 1 
the theoretical prevalence for combined carriers of FIIG2021 OA and FXIII-A V34L is 
1.5% (47.0% x 3.2%) in MI patients and 0.48% (47.8% x 1 %) in controls (Figure-2). The 
observed prevalence of combined carriers in the MI patient population (2.4%; 12 of 500) 
was 1.6-fold higher than its theoretic prevalence (1.5%), and in normal control population 
(0.2%; 1 of 500) was 2.4-fold lower than its theoretic expected prevalence (0.48%). The 
observed prevalence of combined carriers was 12-fold higher in MI patient compared 
with the control population (P = 0.002). 
The interaction between the FIIG20210A and the FXIII-A V34L was further 
examined by analysis of the distribution of FXIII-A V34L in sub-grouped patients and 
controls who carry FIIG20210A as a genetic background. Although the FXIII-A V34L 
showed an almost equal distribution in our MI patient and control populations, FXIII-A 
V34L alleles were detected in 75.0% (12 of 16) patients with a genetic background of 
FIIG20210A but only in 20.0% (1 of 5) of controls with the same genetic background 
(OR 3.7, 95% CI 2.4-5.1, P = 0.013) (Figure-3). 
Of 13 combined carriers of FIIG20210A and FXIII-A V34L identified from the 
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studied population (500 patients and 500 controls), 12 subjects (92.3%), including 7 
males and 5 females, belonged to the MI patient population but only 1 male (0.7%) from 
the control population. The co-existence of these two gene variants imparts a strong 
predisposition for MI with high penetrance. 
FVL and FXIII-A V34L: 
The prevalence of combined carriers of FVL and FXIII-A V34L were similar in 
both MI patient (9 of 500, 1.8%) and control (12 of 500, 2.4%) groups and was consistent 
with their expected frequencies (2.16% in patients and 2.2% in controls). We further 
analyzed the prevalence of FXIII-A V34L in patients and controls who carry the FVL 
allele as a genetic background. The prevalence of FXIII-A V34L was slightly higher in 
the sub-grouped controls (12 of 23, 52.17%) than in the sub-grouped patients (9 of 23, 
39.1 %) but the difference was not statistically significant. 
FIIG2021 OA and FVL: 
There were no combined carriers of FIIG2021 OA and FVL in the MI patient or 
control populations. This is expected considering a calculated expected frequency of 
combined carriers of 0.13% in MI patients and 0.01% in normal controls, respectively. 
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Figure-2: Comparison between the theoretic and observed prevalence of combined 
carriers of mutations in MI patients and healthy controls. 
2.50°/o 
a b 
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0.50°/o 
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a) Comparison between the theoretic (TP) and observed (OP) prevalence of combined carrier for FII20210A 
+ FXIII-A V34L in MI patients; and 
b) Comparison between the expected and observed prevalence of combined carrier for FII20210A + FXIII-
A V34L in healthy controls 
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Figure-3: Prevalence of FXIll34L in MI patients and Healthy Controls who carry 
the FII20210A allele 
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Discussion 
Our results showed that the prevalence of FVL and FXIII-A V34L in the 
Newfoundland population are consistent with those reported from other Caucasian 
populations elsewhere. However, the 1% prevalence of FIIG2021 OA determined from the 
Newfoundland population was lower than that reported from most other Caucasian 
populations (2.0- 2.5%)71 . 
Although of lower prevalence in the Newfoundland population, the FII 2021 OA 
allele was still shown to be 3.3-fold higher in MI patients compared with the control 
population. The prevalence of FII 2021 OA is even higher among MI patients with early 
onset age (5.6-fold higher) compared with age-matched controls. This may suggest that 
FII 2021 OA is important for early age of onset of MI. The low frequency of the FII 
20210A allele in Caucasians and extremely low frequencies in other populations43 ,44 ,47 '212 
indicates that the FII 2021 OA allele may only contribute to the pathogenesis of MI in a 
small portion of MI patients. 
FVL is commonly recognized as a strong risk factor in the pathogenesis of venous 
thrombosis; however the majority of studies have thus far failed to show an association 
between FVL and MI52 '61 '213 . Recently, some studies have suggested that FVL may be 
associated with early onset MI64'208 and MI with normal coronary angiographl6 . 
Although there was identical prevalence of FVL ( 4.6%) in both our patient and control 
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populations, the prevalence of FVL in patients with early onset age was 3.4-fold higher 
than patients with later onset age and 2.7-fold higher than age-matched controls. These 
data suggest a possible thrombotic predisposition of FVL for early onset of MI. 
Furthermore, the prevalence of FVL was higher in male MI patients than female MI 
patients by almost three fold. Nevertheless, the proportion of male MI patients with FVL 
was not significantly different from males in the control group (p=O.ll 0). It is not 
possible with this data to suggest FVL as a gender specific risk factor for MI. As only a 
relatively small number of early onset MI patients have been studied, further efforts 
focusing on FVL in other early onset MI patients and on possible gender differences will 
be of value. 
FXIII-A V34L has been proposed as a protective factor against MI because of the 
reduced prevalence observed in MI patients. We observed a slightly but non-significantly 
lower prevalence of FXIII-A V34L in MI patients (47.0%) compared with our control 
population (47.8%). However, homozygosity for the L allele was more frequently 
observed in MI patients than in controls (8.4% vs. 6.4%) and the gene frequency for 
FXIII-A V34L was similar in both patient and control populations. This data suggests that 
FXIII-A V34L does not confer a protective role against MI. Comparison of male MI 
patients to female MI patients showed an almost 2 fold higher prevalence of FXIII-A 
V34L in males. Comparison of male MI patients with FXIII-A V34L to males in the 
control group showed a significantly higher prevalence among MI patients (p=0.012). 
This data suggests that FXIII-A V34L may impart an increased risk for MI that is 
influenced by gender. 
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Genetic predisposition for MI can result from either an additive effect of several 
genes or a synergistic effect from interactions between multiple genes. Each of these 
genes may only make a small contribution to the global pathogenesis of MI. In our study, 
an interaction between FII 20210A and FXIII-A V34L was identified based on the 
distribution disequilibrium of combined carriers among MI patients. The prevalence of 
combined carriers in MI patients was higher than expected, but lower than expected in 
controls. FXIII-A V34L shows equal carrier frequency in both MI patients and controls 
and does not seem to independently predispose for MI. Furthermore, FII 20210A itself 
showed only a 3.2-fold increased risk for MI. However, combined carriers of FII 2021 OA 
and FXIII-A V34L showed a 12-fold increased risk for MI. These results indicate that the 
interaction of FII 2021 OA and FXIII-A V34L forms a synergistic rather than an additive 
effect in the pathogenesis of MI. In our study, penetrance of MI in individuals carrying 
both FIIG20210A and FXIII-A V34L alleles was 92.3%. We, therefore, conclude that co-
existence of the FII 2021 OA allele with the FVIIIV34L allele is a strong predisposing 
factor for MI. 
The possibility has been considered that since the Newfoundland population is 
descended from a relatively small number of founders that a closely linked gene rather 
than FXIII-A V34L may be the causative mutation. This, however, is a considerably less 
likely possibility for a number of reasons. Firstly there is a very close biochemical 
functional relationship between FXIII and FII. The two factors are very closely related 
sequentially in the clotting cascade. Activated FII (thrombin) is responsible for generation 
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of fibrin from fibrinogen. Fibrin monomers quickly polymerize into larger polymers. 
These are relatively loosely held together. Activated FII also activates FXIII which helps 
strengthen the clot by crosslinking fibrin chains. The reinforced clot is much more 
resistant to fibrinolysis by plasmin. Secondly, the FII 2021 OA allele is observed to 
correlate with elevated levels of prothrombin in plasma, which may enhance activation of 
FXIII leading to a greater tendency toward thrombosis. Thirdly, the FXIII-A V34L 
variant allele has been clearly shown to be much more prone to activation by thrombin 
than the wild type allele: FXIII-A V34L variant results in an amino acid substitution 4 
residues from the thrombin cleavage site that enhances the rate of activation by 
thrombin112 . Both heterozygotes and homozygotes for the FXIII-A V34L allele display 
increased sensitivity to activation by thrombin112 '205 while a more significant increase in 
FXIII activation occurs in homozygotes for FXIII-A V34L112'205 . No doubt the higher 
levels of the FXIII-A V34L enzyme can create a greater risk for plasmin resistant clots. 
Our data suggests that the increased FXIII activity due to FXIII-A V34L alleles is not in 
itself sufficient to impart a significant effect on the development of MI. However, the co-
existence of both FII 20210A and FXIII-A V34L alleles results in a synergistic 
enhancement of prothrombotic tendency through interaction of the two gene products at 
the biochemicallevel112 . Specifically, higher tendency for clot formation by higher levels 
of FII with the FII 2021 OA allele coupled with a tendency for greater resistance to 
fibrinolysis due to greater FXIII activity by the FXIII-A V34L allele. This enhanced 
prothrombotic tendency could result in a greater risk for MI in individuals carrying both 
variants. 
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Typical of a later onset disease, 90% of our patients had their MI at age 50 or 
older. Only 25% of our controls were within this older age group. It is very possible that 
some of our controls under age of 50 will develop MI later in life. This may result in 
underestimation of the true risk associated with certain alleles. The positive associations 
described here would only be strengthened by such an underestimation. Other alleles 
found to impart no significant risk for MI may in fact be weak risk factors. We also 
recognize the small number of individuals in the control and patient group carrying the 
FII 2021 OA allele. Although, the difference in carrier frequency for this allele was 
significantly greater in the younger MI patient group, this observation would be 
strengthened further by exammmg a larger number of younger individuals with MI. 
Further studies exammmg more MI patients and age-matched controls in the 
Newfoundland as well as other populations will be of even greater value to more clearly 
establish the magnitude of risk imparted by presence of these genetic risk factors. These 
studies are currently underway. 
In summary, we analyzed three gene variants, FII 20210A, FVL and FXIII V34L 
m 500 patients with MI and 500 normal controls from a genetically isolated 
Newfoundland population. The FII 20210A was associated with MI and possibly more 
important for early age of onset of MI. FVL was only associated with MI in patients with 
early onset age. A strong predisposition for MI results from interaction between FII 
20210A and FXIII-A V34L alleles as was suggested by a 12-fold increased prevalence of 
combined carriers in MI patients compared with controls. There was also a very high 
penetrance (92%) ofMI in combined carriers. Therefore we conclude: 1) FII 20210A is a 
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genetic risk factor for MI, possibly for early onset; 2) FVL predisposes for early onset of 
MI; 3) FXIII-A V34L may independently predispose to MI in males only; 4) interaction 
between FII 20210A and FXIII-A V34L results in a synergistic co-effect which strongly 
predisposes to MI. Combined carriers of both FII 2021 OA and FXIII-A V34L are at very 
high risk for MI. 
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Myocardial infarction (MI) is known to be a complex multifactorial polygenic 
disease involving several complex and as yet unknown interactions between genes and 
environment. It has recently been demonstrated that several different SNPs may play a 
role in the pathogenesis of MI. In the blood coagulation pathway, the R353Q 
polymorphism of the coagulation factor VII gene (FVII R353Q) has been shown to confer 
a protective effect against MI127•128 '135•136, while in the pathway for the metabolism of 
homocysteine a SNP at nucleotide 1298 (A1298C) in the gene that codes for the enzyme 
5, 10-Methylenetetrahydrofolate reductase (MTHFR) which catalyzes the reduction of 5, 
1 0-methylenetetrahydrofolate to 5-methyltetrahydrofolate have been frequently 
associated with cardiovascular disease188-190' 193 . Also, high base-line levels of one of the 
most widely accepted markers for systemic inflammation, C - reactive protein (CRP), 
have been implicated in the occurrence of MI and cardiovascular disease148-151 . 
Interleukin-6 (Il-6) is the primary determinant of hepatic production of CRP154, and a 
known promoter polymorphism in the Il-6 gene located at nucleotide -17 4 upstream from 
the start of transcription (G>C) has been shown to increase circulating CRP. However, 
inconsistent results for each of these have also been reported by a number of different 
studies 124-126•170•191 . The role ofthese SNPs in the pathogenesis ofMI remains unknown. 
In order to further investigate the relationship between these polymorphisms and 
MI, we simultaneously analyzed the frequency of the MTHFR A1298C, FVII R353Q, 
and Il-6 -174 G/C polymorphisms in 500 biochemically verified MI patients and 500 
healthy individuals in the genetically isolated Newfoundland population. The island 
portion of the Canadian province of Newfoundland and Labrador is located in the 
Atlantic Ocean, off the eastern coast of Canada. The population of the island of 
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Newfoundland consists mainly of descendants of English and Irish settlers who arrived in 
the 181h and 191h centuries196 . The geographical and social isolation of this island has lead 
to very little inward migration for several hundred years 197 and the population remains 
genetically isolated. With a relatively homogenous genetic background, the population is 
an ideal subject for the study of complex multifactorial diseases such as MI. In order to 
determine the individual and combined influence of these gene variants on the occurrence 
of MI, we simultaneously analyzed the frequency of the FVII R353Q, MTHFR A1298C 
and Il-6 -174 G/C polymorphisms in 500 biochemically verified MI patients and 500 
healthy individuals in the genetically isolated Newfoundland population. 
Patients and controls were selected as described previously 14 . Genomic DNA was 
isolated from the peripheral blood using standard methods200 . Genotyping of the FVII 
R353Q, MTHFR A1298C and Il-6 -174G/C were performed by PCR amplification of 
each of the target alleles from genomic DNA followed by restriction digestion with each 
of corresponding enzymes 134' 192 '160 . The prevalence of each gene variant was calculated 
by counting the total carrier frequency including heterozygotes and homozygotes. The 
allele frequencies were determined by gene counting. Pearson Chi Square statistical 
analysis was performed using SPSS vlO.O to test the association between genotypes and 
the prevalence of MI. Odds ratios (OR) were calculated as a measure of the relative risk 
for MI and were given with 95% Cis. The detailed results of the genotyping are given in 
Table 5.1. 
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Table-5.1: Distributions of genotypes, and carrier and allele frequencies of FVII 
R353Q, MTHFR A1298C and IL-6 -174 G/C in MI patient and healthy control (HC) 
populations. 
Genotype MI (n = 500) HC (n = 500) OR P value 
A/A 156 (31.2%) 237 (47.4%) 
MTHFR A1298C A/C 288 (57.6%) 215 (47.0%) 
C/C 56 (11.2%) 48 (9.6%) 
Carrier F. 68.8% 52.6% 1.3 p<0.001 
Allele F. 40.0% 31.1% 
R/R 416 (83.2%) 410 (82.0%) 
FVII R353Q R/Q 82 (16.4%) 86 (17.2%) 
Q/Q 2 (0.4%) 4 (0.8%) 
Carrier F. 16.8% 18.0% 0.93 NS 
Allele F. 8.6% 9.4% 
GIG 166 (31.2%) 157(31.4%) 
Il-6 -174 G/C G/C 257 (51.4%) 255 (51.0%) 
CIC 77 (15.4%) 88 (17.6%) 
Carrier F. 66.8% 68.4% 0.98 NS 
Allele F. 41.1% 43.0% 
The MTHFR 1298C allele shows a prevalence of 52.6% in the Newfoundland 
population which is higher compared with other reported Caucasian populations 
( 0/u) 193 •194 . the The MTHFR A1298C allele interestingly shows a significantly increased 
prevalence in our MI patients (68.8%) compared to our healthy controls subjects (52.6%) 
(p<0.001, OR 1.3, 95% CI 1.1-1.8). 
Although the FVII 353Q allele shows a slightly higher prevalence in our healthy 
controls (18%) than compared to our MI patients (16. 8% ), the small difference does not 
give statistical significance. Our results therefore, do not support a protective role of FVII 
353Q in MI, which has been suggested in previous studies123-131 . 
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The Il-6 -17 4 G/C allele shows a similar prevalence in both our MI patients and 
healthy controls (66.8% vs 68.4%). Therefore our data does not suggest an association 
between Il-6 -174 G/C and MI. However, at this moment, we cannot completely mle out 
CRP as a genetic risk factor for MI, as several other novel reported variations within the 
CRP gene or its regulators have yet to be studied. These markers are currently being 
examined in our laboratory as part of our ongoing study into genetic risk factors in MI. 
A multivariate analysis using logistic regression was also employed in the analysis 
in order examine the effect of the presence of multiple polymorphisms upon the presence 
or absence of a MI. No association was found between any combination of two or more 
genes. 
It is worth noting that with respect to the results obtained for the FVII R353Q, MTHFR 
A1298C, and Il-6 -174 G/C mutations, possible interactions with other nearby proteins in 
their respective systems were not examined. It is possible for instance, much like the 
gene-gene interaction between FII 20210A and FXII-A (reference), that FVII R353Q may 
interact with other polymorphic proteins such as tissue factor, FIX or FX to reduce the 
action of the coagulation cascade and actually function in the protective role others have 
attributed to it. Likewise, the MTHFR A1298C gene variant may be influenced by the 
presence of the C677T mutation or other polymorphic markers in the homocysteine 
metabolic pathway, and Il-6 may react with other cytokines in the inflammation pathway 
to influence the occurrence of an MI. The investigation of further gene polymorphisms in 
these pathways in the Newfoundland and other populations will be of tremendous benefit 
to clinicians world-wide in the diagnosis and counselling of patients abnormally 
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predisposed to suffer MI. The observations reported here would be further strengthened 
by examining an increased number of patients with MI. This effort is currently underway. 
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6 
CONCLUSIONS 
AND FUTURE RESEARCH 
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6.1 Conclusions 
Myocardial Infarction is a complex multifactorial disease resulting from 
contributions from an individual's lifestyle (including smoking, activity levels and diet), 
as well as the development of atherosclerosis, thrombophilia and inflammation, and the 
genes which control these. The level at which genetics contribute to the development of 
an MI is still the subject of much debate. The results in our study into the role of genetic 
polyrnorphisms in the blood coagulation and metabolic systems indicate: 1) There is a 
significant and highly heterogeneous and ethnic-dependent distribution of the FVL, and 
FXIIIV34L variants between Chinese and Newfoundland Caucasian populations. The 
Chinese population shows a 5-fold lower prevalence of FIIG2021 OA, a 23-fold lower 
prevalence of FVL and 240-fold lower prevalence of FXIII34L compared with our 
Newfoundland Caucasian controls. 2) The prevalence of FVL and FXIII-A V34L in the 
Newfoundland population are consistent with those reported from other Caucasian 
populations elsewhere. However, the 1% prevalence of FIIG2021 OA determined from the 
Newfoundland population was lower than that reported from most other Caucasian 
populations (2.0 - 2.5%). 3) FIIG2021 OA is a genetic risk factor for MI, possibly for 
early onset. 4) FVL predisposes for early onset of MI. 5) FXIII-A V34L may 
independently predispose to MI in males. 6) Interaction between FIIG2021 OA and FXIII-
A V34L results in a synergistic co-effect which strongly predisposes to MI. Combined 
carriers of both FIIG20210A and FXIII-A V34L are at very high risk for MI. 7) There is 
no association between aMI and a protective role for the FVII R353Q gene variant in the 
Newfoundland population. 8) The MTHFR A1298C polymorphism is associated with MI 
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in the Newfoundland population, and at a frequency of 47.4% this allele has a higher 
prevalence within the Newfoundland population than has been reported in other 
Caucasian populations (25- 35%). 9) The Il-6 -174G/C promoter polymorphism does not 
appear to play a role in the pathogenesis of MI. 1 0) A multivariate analysis using logistic 
regression was also employed in the analysis in order examine the effect of the presence 
of multiple polymorphisms upon the presence or absence of a MI. No association was 
found between any combination of two or more genes other than between FII 2021 OA and 
FXIII-A 341. 
6.2 Future Research 
It is worth noting that with respect to the results obtained for the FVII R353Q, 
MTHFR A 1298C, and Il-6 -17 4 G/C mutations, possible interactions with other nearby 
proteins in their respective systems were not examined. It is possible for instance, much 
like the gene-gene interaction between FII 20210A and FXII-A 34L described in chapter 
4 of this thesis, that FVII R353Q may interact with other polymorphic proteins such as 
tissue factor, FIX or FX to reduce the action of the coagulation cascade and actually 
function in the protective role others have attributed to it. Likewise, the MTHFR A1298C 
gene variant may be influenced by the presence of the C677T mutation in MTHFR or 
other polymorphic markers in the homocysteine metabolic pathway, and Il-6 may react 
with other cytokines in the inflammation pathway to influence the occurrence of an MI. 
The investigation of further gene polymorphisms in these pathways in the Newfoundland 
and other populations will be of tremendous benefit to clinicians world-wide in the 
diagnosis and counselling of patients abnormally predisposed to suffer MI. 
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